Dietary Supplements:  PIE | COLUMN | TOP 25: Citations [or Observations] | Warning Letters 
 FSMA [New!] | 483 Reverse Lookup | Classifications | Regulatory Action Reports | OpenFDA: CAERs | Recalls 


This chart indicates the total number of observations by fiscal year found during FDA inspections of dietary supplement companies under 21 CFR 111 cGMPs, including adverse events (FDCA 761).


DISCLAIMER: These charts are compiled from FDA data. The author does not guarantee that all information provided is accurate and complete, as FDA may redact certain information from the published datasets. Please confirm your conclusions by checking at the FDA web site: Inspection Classifications and  Inspection Observations or make a FOI request to FDA. I will be glad to make a FOI request on your behalf, please contact me.


All charts and tables are ©2018 Marian Boardley Consulting LLC. If you found this information useful, please consider making a $5 contribution (suggested) at paypal.me/MarianBoardley. Thank You!